Navigation Links
Bunge Reports Fourth Quarter Net Income of $245 Million
Date:2/7/2008

859 4,515

Long-term debt 3,435 2,874

Deferred income taxes 149 180

Other non-current liabilities 876 700

Minority interest in subsidiaries 752 410

Shareholders' equity 7,945 5,668

Total liabilities and shareholders' equity $22,016 $14,347

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In millions)

(Unaudited)

Year Ended

December 31,

2007 2006

OPERATING ACTIVITIES

Net income $778 $521

Adjustments to reconcile net income to cash

used for operating activities:

Foreign exchange gain on debt (285) (175)

Impairment of assets 70 20

Bad debt expense 48 41

Depreciation, depletion and amortization 385 324

Stock-based compensation expense 48 19

Deferred income taxes (62) (191)

Gain on sale of assets (22) (36)

(Increase) decrease in the allowance for

recoverable taxes (47) 5

Minority interest 146 60

Equity in earnings of affiliates (33) (23)

Changes in operating assets and liabilities,

excluding the effects of acquisitions:

Trade accounts receivable (319) (69)

Inventories
'/>"/>

SOURCE Bunge Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
2. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
3. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
4. Recent Research Reports and Near-Term Corporate Events
5. Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results
6. Thermo Fisher Scientific Reports Record 2007 Fourth Quarter Revenues and Operating Performance; Provides Guidance for 2008
7. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
8. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
9. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
10. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
11. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3